1,890 search results for “drug discovery” in the Public website
- About this minor
-
Advanced in vitro models for studying drug induced toxicity
Promotor: Prof.dr. B. van de Water, Co-promotor: L.S. Price
-
Drug-target binding kinetics in vivo
A next, general pharmacological problem to be tackled is how drug-target binding kinetics in vivo, affects target occupancy as an important indicator of the time-course of drug effects.
-
Novel Chemical Modalities
The Novel chemical modalities research group is headed by Assistant Professor Sebastian Pomplun. Sebastian started at the division of Medicinal Chemistry within the LACDR in September 2021. His lab develops technologies for the discovery of novel chemical modalities that can address challenging drug…
-
Drug use and harm reduction policies
Harm reduction in practice: a comparative analysis of the Dutch and Brazilian approach towards drug users.
-
Translational pharmacokinetics-pharmacodynamics in zebrafish: integration of experimental and computational methods
The zebrafish is a promising vertebrate model organism in early drug discovery and development.
-
Molecular Pharmacology
In this research group, headed by Laura Heitman, novel receptor concepts in drug discovery are studied, aiming to increase the effectivity of medicines. Many drugs act via so-called G protein-coupled receptors (GPCRs) and therefore our research is mainly focused on understanding and improving drug-receptor…
-
Career prospects
In the Master’s programme in Bio-Pharmaceutical Sciences of Leiden University you are trained for a scientific career in drug research and development.
-
The activation mechanisms of G protein-coupled receptors: the case of the adenosine A2B and HCA2/3 receptors
Promotor: A.P. IJzerman
-
Illuminating N-acylethanolamine biosynthesis with new chemical tools
In this thesis, the discovery and optimization is described of chemical tools to study the N-acylethanolamine (NAE) biosynthetic pathway.
-
Chemical genetic approaches for target validation
Drug development is a time- and resource-consuming process that starts with the discovery and validation of a (protein) target that contributes to pathogenesis or disease progression.
-
Two-pronged attack on infectious diseases
A combination of two potential drugs gives hope of a 'super blockage' of an over-active immune system, Leiden researchers report in Nature. The breakthrough came from the crystallisation of a membrane protein.
-
Phenotypic screening with 3D cell-based assays
Traditional drug discovery approaches have been hampered by (in vitro) cell-culture models that poorly represent the situation in the human body.
-
Inhibitor Selectivity: Profiling and Prediction
Less than 1 in 10 drug candidates that enter phase 1 clinical trials actually gets approved for human use.
-
From discovery to business: 'In the lab, we often don't realise that we are working to help an immense number of patients'
'It gave our team a big boost to hear that our work was valuable,' says medical chemist Elmer Maurits about the moment they won the Venture Challenge. With their company Iprotics, they want to develop a drug that can better treat patients with autoimmune diseases and blood cancers. 25,000 euros of prize…
-
Discovery of Reversible Monoacylglycerol Lipase Inhibitors
Monoacylglycerol lipase (MAGL) is the principal enzyme responsible for hydrolysis of the endocannabinoid 2-arachidonoylglycerol (2-AG). MAGL inhibition provides several potential therapeutic opportunities, including anti-nociceptive, anti-inflammatory and anti-cancer activity.
-
Research
The research conducted at the Leiden Academic Centre for Drug Research is clustered within the divisions of BioTherapeutics, Drug Discovery & Safety and Systems Biomedicine and Pharmacology, and the Metabolomics and Analytics Centre.
-
Flagships
In CCLS several subgroups have formed, below you can find an overview of these groups with the names of the leading researchers and a short outline of the project.
-
Quantitative systems pharmacology modeling of biotherapeutics in oncology
In this thesis, mathematical modeling and simulation was applied as a tool to inform quantitative decision making in oncology drug discovery and development.
-
Programme structure
The Drug Discovery and Safety specialisation consists of compulsory and optional components.
-
Using AI to improve the Design-Make-Test cycle with Galapagos
Researchers at LED3 are working together with biopharmaceutical company Galapagos to develop software for use in early drug discovery (funded by NWO). This software is able to design molecules with several simultaneously optimized characteristics and will also take prediction reliability into consideration…
-
Knowledge discovery from patient forums: gaining novel medical insights from patient experiences
Patients share valuable advice and experiences with their peers in online patient discussion groups.
-
Organisation
The Leiden Academic Centre for Drug Research (LACDR) is responsible for the research and education in Bio-Pharmaceutical Sciences carried out at Leiden University.
-
Pedagogies of Prohibition: Time, Education, and the War on Drugs in Rio de Janeiro’s Zona Norte
Benjamin Fogarty-Valenzuela published the article 'Pedagogies of Prohibition: Time, Education, and the War on Drugs in Rio de Janeiro’s Zona Norte' in Cultural Anthropology 37. The article’s three sections focus on three forms of temporal control—busyness, punctuality, and rhythm—and each demonstrates…
-
Pharmacometabolomics; prediction of system-wide multi-biomarker drug response
The lack of success of new CNS drugs in clinical development is in part due to the complexity of the CNS, unexpected side effects, difficulties for drugs to penetrate the brain, but also by the lack of biomarkers.
-
LED3 PhD-Postdoc Symposium 2024
Conference
-
Targeting the adenosinergic system
Adenosine is an endogenous ligand which exerts its action by activating adenosine receptors (ARs), while its circulating levels are controlled via a variety of mechanism and proteins, amongst others the equilibrative nucleoside transporters (ENTs).
-
Pharmacogenomics in drug development: implementation and application of PKPD model based approaches
Promotor: Prof.dr. M. Danhof, Co-Promotor: J. de Jongh
-
History
Life Sciences Artificial Intelligence Data Science
-
Why Leiden University?
We are committed to provide you with meaningful, rigorous and quality graduate experiences in a personalized environment with a cutting edge research infrastructure and internationally renowned supervisors.
-
Determining the kinetic profile of ENT1 inhibitors
Supervisor: Anna Vlachodimou
-
mRNA and drug delivery with lipid-based nanoparticles
This thesis focuses on the application of lipid-based nanomedicine in drug delivery, including small molecular antitumor drugs and biomacromolecules including mRNA, and evaluates their biological performance.
-
Finding unique drug structures with artificial intelligence and chemistry
In the search for new medicines against diseases such as cancer, a Leiden team has developed a new workflow. This approach combines artificial intelligence (AI) with molecular modelling and is suitable for finding unknown and innovative drug structures, the researchers proved.
-
24-hour rhythms in drug exposure and effect
Although rarely considered by the pharmaceutical industry or clinicians, 24-hour rhythms in physiology are a factor of potential influence on the pharmacokinetics and pharmacodynamics of drugs.
-
Spatial (3-D) CNS drug distribution in vivo
Another research line is the development of a spatial CNS drug distribution model, by ultimately including the 3-dimensional anatomical organization of the CNS.
-
Why don't drugs make it to the market?
How can we extend the drug residence time to combat diseases more effectively?
-
How Oncode-PACT is bringing new cancer medicines closer with 325 million in Growth Fund money
How can you ensure that more experimental drugs reach the finish line? At the moment, only one in twenty cancer drugs that are tested on humans makes it to the market. This is an enormous loss for patients and society. With a grant from the National Growth Fund, Oncode-PACT aims to efficiently select…
-
PROPER: ‘Near-patient’ prostate cancer models for the assessment of disease prognosis and therapy
How to identify patients at risk of developing devastating, metastatic disease and facilitate the development of personalised treatment for prostate cancer patients?
- Contact
-
Discovery and characterization of new glucosylated metabolites: pathophysiological consequences
Within this thesis the central stage is taken by the discovery and investigation of transglycosylation of sterols. First, investigation focuses on the development of a method to accurately detect and quantify glucosylated metabolites in biological materials.
-
From lab discovery to a new drug: the Venture Challenge makes it possible
A breakthrough from the PhD research of medical chemist Elmer Maurits may help patients with autoimmune diseases and blood cancer in the future. But bringing a discovery from the lab to the clinic is not so easily done. Thanks to NWO's Venture Challenge, Maurits and his team will receive ten weeks of…
-
Oncode Accelerator
Providing each cancer patient with the right treatment remains a challenge. Oncode Accelerator aims to change this by innovating the way we develop cancer treatments, thus ensuring the patient is at the heart of the process. Leiden University, the LUMC and other partners will implement this new way…
-
European Lead Factory
The European Lead Factory has been created with the ultimate goal to develop lead drug candidates to address neglected diseases including bacterial infections, psychiatric disorders and oncology.
-
Finding and valorizing new antibiotics using AI
Antibiotics are a class of medicine most people take for granted. But pathogenic bacteria are becoming more and more resistant to our antibiotics, and this poses a great challenge for future treatments. There is thus a great societal need to identify new molecules that can address new targets and be…
-
NMR studies of protein-small molecule and protein-peptide interactions
Promotor: M. Ubbink, Co-promotor: G. Siegal
-
Antibiotic combination therapies against drug resistant Gram negative pathogens
Can effective synergists be identified to enhance the effect of antibiotics against Gram negative pathogens?
-
Steffen Brünle
Science
s.bruenle@lic.leidenuniv.nl | +31 71 527 4544
-
Chemical Probe Facility
The Chemical Probe Facility is part of the Leiden Early Drug Discovery & Development (LED3) center. Activity-based protein profiling (ABPP) is one of the pillars of chemical biology. ABPP determines the activity of entire protein families in living cells and tissues under physiological conditions, such…
-
Teaching
At Molecular Physiology we teach the following courses within the Leiden Institute of Chemistry's Chemistry and Life Science and Technology programmes.
-
Zebrafish embryos and larvae as a complementary model for behavioural research
Promotor: Prof.dr. M.K. Richardson